lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

3 rows where filing_uuid = "fcd44b10-4df2-4c2e-9fa6-a9152eefc6e9" and issue_code = "HCR" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: received_date (date)

issue_code 1

filing_year 1

filing_period 1

id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3330460 AMERICAN SOCIETY OF HEMATOLOGY fcd44b10-4df2-4c2e-9fa6-a9152eefc6e9 Q1 AMERICAN SOCIETY OF HEMATOLOGY 59171 AMERICAN SOCIETY OF HEMATOLOGY 2025 first_quarter HCR Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Born-Alive Abortion Survivors Protection Act (H.R. 21/S. 6) Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721) Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   30000 0 0 2025-04-09T13:43:02-04:00
3531322 AMERICAN SOCIETY OF HEMATOLOGY fcd44b10-4df2-4c2e-9fa6-a9152eefc6e9 Q1 AMERICAN SOCIETY OF HEMATOLOGY 59171 AMERICAN SOCIETY OF HEMATOLOGY 2025 first_quarter HCR Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Born-Alive Abortion Survivors Protection Act (H.R. 21/S. 6) Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721) Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   30000 0 0 2025-04-09T13:43:02-04:00
3602527 AMERICAN SOCIETY OF HEMATOLOGY fcd44b10-4df2-4c2e-9fa6-a9152eefc6e9 Q1 AMERICAN SOCIETY OF HEMATOLOGY 59171 AMERICAN SOCIETY OF HEMATOLOGY 2025 first_quarter HCR Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Born-Alive Abortion Survivors Protection Act (H.R. 21/S. 6) Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721) Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   30000 0 0 2025-04-09T13:43:02-04:00

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);